banner

Investors

At Acadia, we remain deeply committed to providing important new therapies to patients and delivering value for our stockholders. Our Investor Center is designed to provide you with convenient access to company information.

Recent News

05/04/22
- 1Q22 net sales of $115.5 million , an 8% increase over 1Q21 - Reiterating FY22 net sales guidance of $510 to $560 million - FDA Advisory Committee meeting to review sNDA for pimavanserin for the treatment of ADP scheduled for June 17, 2022 SAN DIEGO --(BUSINESS WIRE)--May 4, 2022-- Acadia
05/03/22
SAN DIEGO --(BUSINESS WIRE)--May 3, 2022-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: BofA Securities 2022 Healthcare Conference Fireside Chat: Tuesday, May 10, 2022 at 3:20 p.m.
05/02/22
SAN DIEGO --(BUSINESS WIRE)--May 2, 2022-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that a virtual meeting of the U.S. Food and Drug Administration's   Psychopharmacologic Drugs Advisory Committee to review the resubmitted supplemental New Drug Application (sNDA) for pimavanserin